[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Lahore General Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":73},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100629108","phase-2-comparison-of-functional-outcomes-following-arthroscopic-acl-reconstruction-with-peroneus-longus-autograft-with-and-without-intra-articular-platelet-rich-plasma-injection-100629108",false,"NCT07470359","Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection.","Comparison of Functional Outcomes Following Arthroscopic ACL Reconstruction With Peroneus Longus Autograft With and Without Intra-articular Platelet-Rich Plasma Injection: A Randomized Controlled Trial","Inclusion Criteria: Age between 18 and 50 years. Diagnosis of a primary, complete ACL tear requiring reconstruction. Willingness to undergo arthroscopic ACL reconstruction with peroneus longus autograft.\n\nActive individuals participating in sports or regular physical activity. Willingness to provide informed consent and adhere to the study protocol, including follow-up visits and rehabilitation.\n\nAbility to understand and complete study questionnaires. - Exclusion Criteria: Previous knee surgery on the affected limb. Concomitant ligamentous injuries requiring additional reconstruction (e.g., PCL, MCL, LCL Grade III).\n\nSignificant chondral damage (Outerbridge grade \\> 2 on pre-operative MRI or intra-operative assessment).\n\nPre-existing knee osteoarthritis (Kellgren-Lawrence grade \\> 2). Systemic inflammatory conditions (e.g., rheumatoid arthritis). Bleeding disorders or coagulopathies. Current use of anticoagulants. Corticosteroid injection into the knee within 6 weeks prior to surgery. Pregnancy or lactation. Inability to comply with the rehabilitation protocol. Infection or history of infection in the affected knee. History of previous contralateral ACL injury (to isolate primary injury outcomes).\n\n\\-","ALL","18 Years","50 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This prospective RCT investigates if a single 4 ml intra-articular PRP injection improves knee function after ACL reconstruction using peroneus longus autograft. In Pakistan's resource-limited context, 88 patients (18-50 years) with isolated ACL tears receive either PRP or saline during surgery, then randomized equally. KOOS4 scores compared at 3, 6, and 12 months via ANCOVA (adjusted baseline, α=0.05). Positive results could establish affordable enhancement for recovery and guide practice in similar settings.",[27,28,29],"ACL Reconstruction","Intraarticular Injection","PRP",[31,32],"Anterior Cruciate Ligament, ACL Reconstruction, Peroneus Longus Autograft, Platelet-Rich Plasma, Intra-articular Injection","Randomized Controlled Trial, KOOS4 Score, Functional Outcomes, Graft Healing, Resource-Limited Settings","RECRUITING","2026-03-10",{"date":36,"type":37},"2026-03-13","ACTUAL",{"date":39,"type":37},"2026-02-20",{"date":41,"type":21},"2027-11-30",{"name":43,"class":44},"Lahore General Hospital","OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100613032","early-phase-1-comparison-between-oral-methotrexate-and-tofacitinib-in-chronic-plaque-psoriasis-100613032","NCT07261306","Comparison Between Oral Methotrexate and Tofacitinib in Chronic Plaque Psoriasis","MTX","Inclusion Criteria:\n\n* Patients aged 18- 70 years of either gender.\n* Only patients with Psoriasis Area and Severity Index (PASI) score of 10 or above, and\u002For Body Surface Area (BSA) involvement of 10% or more, will be included.\n* Duration of plaque psoriasis for at least 6 months prior to the study.\n* Psoriasis that has not shown adequate response to topical therapies\n\nExclusion Criteria:\n\n* Individuals with other forms of psoriasis or other significant dermatological conditions that might interfere with the assessment of psoriasis.\n* Participants currently receiving systemic corticosteroids, biologics, or any other immunosuppressive agents within 4 weeks prior to the start of the study will be excluded.\n* Known hypersensitivity or contraindications to either methotrexate or tofacitinib.\n* History of significant liver, kidney, hematologic\u002Fbleeding disorder, gastrointestinal\u002Facid peptic disease, or immune system disorders.and any history of tuberculosis and malignancy.\n* Pregnant or lactating women will not be eligible for the study.",true,"70 Years",{"count":56,"type":21},75,[58],"EARLY_PHASE1","Psoriasis is a chronic inflammatory dermatoses which include well demarcated scaly erythematous plaques on whole body including scalp role of methotrexate vs tofacitinib is compared in this study",[61],"Psoriasis",[63,64],"MtX","Tofacitinib","2025-11-21",{"date":67,"type":37},"2025-12-03",{"date":69,"type":37},"2025-08-29",{"date":71,"type":21},"2025-12-25",{"name":43,"class":44},""]